Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors

Papadatos-Pastos, D; Yuan, W; Pal, A; Crespo, M; Ferreira, A; Gurel, B; Prout, T; Ameratunga, M; Chenard-Poirier, M; Curcean, A; Bertan, C; Baker, C; Miranda, S; Masrour, N; Chen, WT; Pereira, R; Figueiredo, I; Morilla, R; Jenkins, B; Zachariou, A; Riisnaes, R; Parmar, M; Turner, A; Carreira, S; Yap, C; Brown, R; Tunariu, N; Banerji, U; Lopez, J; de Bono, J; Minchom, A

Minchom, A (通讯作者)，Royal Marsden Hosp, Trug Dev Unit, Inst Canc Res, Sutton, Surrey, England.

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022; 10 (6):

Abstract

Background Data suggest that immunomodulation induced by DNA hypomethylating agents can sensitize tumors to immune checkpoint inhibitors. We conducted......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索